140 related articles for article (PubMed ID: 4584481)
1. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Hutchison JC; Wilkinson WH
Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
[No Abstract] [Full Text] [Related]
2. Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).
Morgan JP; Bianchine JR; Hsu TH; Margolis S
Clin Pharmacol Ther; 1971; 12(3):517-24. PubMed ID: 4936037
[No Abstract] [Full Text] [Related]
3. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Wolfram G; Keller C; Kilani C; Zöllner N
Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
[No Abstract] [Full Text] [Related]
4. Effect of halofenate on serum uric acid.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
Clin Pharmacol Ther; 1973; 14(3):371-3. PubMed ID: 4572799
[No Abstract] [Full Text] [Related]
5. Effect of halofenate on serum lipids.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
[No Abstract] [Full Text] [Related]
6. Studies of the uricosuric action of the hypolipidemic drug halofenate.
Ravenscroft PJ; Sands JM; Emmerson BT
Clin Pharmacol Ther; 1973; 14(4):547-51. PubMed ID: 4723262
[No Abstract] [Full Text] [Related]
7. Comparative study of several hypolipidemic agents related to clofibrate.
Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
[No Abstract] [Full Text] [Related]
8. The metabolic spectrum of halofenate.
Ryan JR
Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of halofenate on serum triglyceride levels.
Aronow WS; Vicario MD; Moorthy K; King J; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1975 Dec; 18(6):855-61. PubMed ID: 813950
[No Abstract] [Full Text] [Related]
10. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
Lisch HJ; Patsch J; Sailer S; Braunsteiner H
Atherosclerosis; 1975; 21(3):391-9. PubMed ID: 1148032
[TBL] [Abstract][Full Text] [Related]
11. Halofenate: effectiveness of two dosage forms and two dose schedules.
Hutchison JC; Wilkinson WH
Atherosclerosis; 1974; 19(3):417-28. PubMed ID: 4133379
[No Abstract] [Full Text] [Related]
12. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Bassett DR; Mikkelsen WM; Buckingham RB; Block WD; Sidiq M; Shakibai A; DiGaetano R; Liou LL
Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
[No Abstract] [Full Text] [Related]
13. Halofenate, serum lipids, and exercise performance in coronary heart disease.
Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
Clin Pharmacol Ther; 1974 Jan; 15(1):67-72. PubMed ID: 4587107
[No Abstract] [Full Text] [Related]
14. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Keller C; Wolfram G; Zöllner N
Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of a new drug MK 185 with clofibrate in the treatment of hyperlipidaemias.
Jepson EM; Small E; Grayson MF; Bance G; Billimoria JD
Atherosclerosis; 1972; 16(1):9-14. PubMed ID: 4341723
[No Abstract] [Full Text] [Related]
16. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
Kuntzen O; Hehl FJ; Walter E; Zimmermann R
Arzneimittelforschung; 1978; 28(12):2349-52. PubMed ID: 227420
[TBL] [Abstract][Full Text] [Related]
17. Halofenate. Its selection and trial as a primary uricosuric agent.
Bluestone R; Campion D; Klinenberg JR
Arthritis Rheum; 1975; 18(6 Suppl):859-62. PubMed ID: 1106434
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
[No Abstract] [Full Text] [Related]
19. One-year trials with halofenate, clofibrate, and placebo.
Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
[TBL] [Abstract][Full Text] [Related]
20. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
Feldman EB; Gluck FB; Carter AC
J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]